1+ hour, 51+ min ago  (115+ words) A new preclinical investigation from the University of California, Riverside, is offering fresh insight into a puzzling trend researchers have observed for years: people who regularly use cannabis often show lower body weight and a smaller likelihood of developing type…...

9+ hour, 51+ min ago  (324+ words) "In the wake of last fall's government shutdown and the ongoing debate over Obamacare subsidies, it has become clear that our healthcare system is experiencing an existential crisis with implications for all of us," Terry writes. "Beyond Medicare for All,…...

11+ hour, 22+ min ago  (123+ words) Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 Bro ADen Phase 1b clinical data and potential across Type 2 inflammatory diseases KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data…...

12+ hour, 10+ min ago  (378+ words) Investing News Network Bria Cell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+ - Bria Cell expands push in women's health, building on Phase 2 success in advanced metastatic breast cancer - Bria-OVA+, Bria Cell's next generation personalized immunotherapy candidate for…...

1+ day, 9+ hour ago  (563+ words) Investing News Network HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia During IND-Enabling Studies HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells BPD is a rare pediatric disease affecting underweight premature infants which the…...

1+ day, 8+ hour ago  (137+ words) Figure 1. 2nd MSA patient on nasal foralumab Significant reduction in basal ganglia and thalamic uptake following nasal foralumab Figure 2. 2nd MSA patient on nasal foralumab Marked reduction in Cerebellar white matter uptake following nasal foralumab Figure 3. 1st MSA patient on nasal foralumab Marked…...

1+ day, 1+ hour ago  (294+ words) In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of Fc'RI-driven pathology versus remibrutinib In healthy volunteers, both single- and multiple-ascending-dose oral dosing of bexobrutideg led to rapid and robust BTK…...

1+ day, 9+ hour ago  (231+ words) TULSA Procedure Talks at AUA2026 A Complete Interventional MRI ("i MRI") Solution for Prostate Ablation To see the future of i MRI prostate ablation first-hand, Profound is pleased to invite AUA2026 attendees to visit Booth #413, where it will host demonstrations of TULSA-PRO…...

1+ day, 7+ hour ago  (131+ words) Because agen T-797 is an off-the-shelf allogeneic therapy administered without patient-specific manufacturing, the product may be particularly well suited for rapid deployment in acute critical care settings where timing and scalability are essential. High-Acuity Critical Care with Global Relevance Importantly, the…...

1+ day, 12+ hour ago  (418+ words) Investing News Network Bria Cell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer - Bria-PROS+ is Bria Cell's next generation personalized off-the-shelf immunotherapy for prostate cancer - Immune stimulating components of Bria-PROS+ enhance anti-tumor responses - Bria Cell has completed manufacturing…...